2008 Clinical Practice Guidelines - Canadian Diabetes Association

Efficacy in Nephropathy. Lancet. 1998;352:1252-1256.
57. Maschio G, Alberti D, Locatelli F, et al. Angiotensin-converting
enzyme inhibitors and kidney protection: the AIPRI trial.
The ACE Inhibition in Progressive Renal Insufficiency (AIPRI)
Study Group. J Cardiovasc Pharmacol. 1999;33(suppl 1):S16-
S20.
58. Shoda J, Kanno Y, Suzuki H. A five-year comparison of the
renal protective effects of angiotensin-converting enzyme
inhibitors and angiotensin receptor blockers in patients with
non-diabetic nephropathy. Intern Med. 2006;45:193-198.
59. Parving HH, Persson F, Lewis JB, et al. Aliskiren combined
with losartan in type 2 diabetes and nephropathy. N Engl J Med.
2008;358;23:2433-2446.
60. Minutolo R, Balletta MM, Catapano F, et al. Mesangial hypercellularity
predicts antiproteinuric response to dual blockade of
RAS in primary glomerulonephritis. Kidney Int.2006; 70:1170-
1176.
61. Bakris GL, Weir MR. Angiotensin-converting enzyme
inhibitor-associated elevations in serum creatinine: is this a
cause for concern? Arch Intern Med. 2000;160:685-693.
62. Reams GP, Bauer JH, Gaddy P. Use of the converting enzyme
inhibitor enalapril in renovascular hypertension. Effect on
blood pressure, renal function, and the renin-angiotensinaldosterone
system. Hypertension. 1986;8:290-297.
63. Franklin SS, Smith RD. Comparison of effects of enalapril
plus hydrochlorothiazide versus standard triple therapy on
renal function in renovascular hypertension. Am J Med. 1985;
79:14-23.
64. Miyamori I, Yasuhara S, Takeda Y, et al. Effects of converting
enzyme inhibition on split renal function in renovascular
hypertension. Hypertension. 1986;8:415-421.
65. Cooper WO, Hernandez-Diaz S, Arbogast PG, et al. Major
congenital malformations after first-trimester exposure to
ACE inhibitors. N Engl J Med. 2006;354:2443-2451.
66. de Zeeuw D, Remuzzi G, Parving HH, et al. Proteinuria, a target
for renoprotection in patients with type 2 diabetic
nephropathy: lessons from RENAAL. Kidney Int. 2004;65:
2309-2320.
67. de Zeeuw D, Remuzzi G, Parving HH, et al. Albuminuria, a
therapeutic target for cardiovascular protection in type 2 diabetic
patients with nephropathy. Circulation. 2004;110:921-927.
68. Keane WF, Brenner BM, de Zeeuw D, et al.The risk of developing
end-stage renal disease in patients with type 2 diabetes
and nephropathy: the RENAAL study. Kidney Int. 2003;63:
1499-1507.
69. Forsblom CM, Groop PH, Ekstrand A, et al. Predictive value
of microalbuminuria in patients with insulin-dependent diabetes
of long duration. BMJ. 1992;305:1051-1053.
70. Zoja C, Benigni A, Remuzzi G. Cellular responses to protein
overload: key event in renal disease progression. Curr Opin
Nephrol Hypertens. 2004;13:31-37.
71. The Diabetes Control and Complications (DCCT) Research
Group. Effect of intensive therapy on the development and
progression of diabetic nephropathy in the Diabetes Control
and Complications Trial. Kidney Int. 1995;47:1703-1720.
72. UK Prospective Diabetes Study (UKPDS) Group. Intensive
blood-glucose control with sulphonylureas or insulin compared
with conventional treatment and risk of complications in patients
with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837-853.
73. Viberti G,Wheeldon NM; MicroAlbuminuria Reduction With
VALsartan (MARVAL) Study Investigators. Microalbuminuria
reduction with valsartan in patients with type 2 diabetes mellitus:
a blood pressure-independent effect. Circulation. 2002;
106:672-678.
S133
COMPLICATIONS AND COMORBIDITIES